Dark

FBIO
Fortress Biotech, Inc.
stock NASDAQ

At Close

May 12, 2025 3:59:31 PM EDT

1.65USD-2.367%(-0.04)154,119

1.64Bid 1.67Ask 0.03Spread

Pre-market

May 12, 2025 8:42:30 AM EDT

1.67USD-1.183%(-0.02)34,763

After-hours

May 12, 2025 4:31:30 PM EDT

1.73USD+4.848%(+0.08)299

OverviewOptionsHistoricalExchangesShortsNews

Jan 25, 2022

04:30PM EST Checkpoint Therapeutics to Participate in the B. Riley GlobeNewswire Inc

07:30AM EST -- Study met primary endpoint with 47.4% objective response rate -- Safety and tolerability profile consistent with previously reported data -- Planned BLA submission on track for later this year -- Conference call to be held today, Tuesday, January 25, 2022, at 8:30 AM ET GlobeNewswire Inc

07:14AM EST FDA Holds Mustang Bio's Gene Therapy IND For Compromised Immune System Disorder Benzinga

Jan 24, 2022

05:33PM EST Mustang Bio Provides Update On Its IND Application For MB-207 Benzinga

Jan 13, 2022

07:00AM EST Franchise includes AMZEEQ for the treatment of acne and ZILXI for the treatment of rosacea, and a development-stage dermatology program (FCD105) along with the MST proprietary platform GlobeNewswire Inc

Jan 7, 2022

02:05PM EST Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for GlobeNewswire Inc

Jan 6, 2022

08:30AM EST Fortress Biotech to Participate in the H.C. Wainwright BioConnect GlobeNewswire Inc

Jan 5, 2022

08:30AM EST Mustang Bio to Participate in Three January 2022 Virtual Investor GlobeNewswire Inc

Dec 21, 2021

09:00AM EST Fortress Biotech to Ring Nasdaq Stock Market Closing Bell on GlobeNewswire Inc

Dec 16, 2021

08:33AM EST Fortress Biotech Announces Initiation Of Phase 2 Clinical Trial Of Triplex For Adults Co-Infected with HIV And CMV Benzinga

08:30AM EST Helocyte, Inc., a partner company of Fortress Biotech, is developing Triplexfor the treatment of cytomegalovirus GlobeNewswire Inc

08:30AM EST Mustang Bio Added to the NASDAQ Biotechnology Index GlobeNewswire Inc

Dec 13, 2021

09:00AM EST 95% overall response rate, 65% complete response rate and favorable safety profile in patientstreatedwithmodified cell manufacturing process GlobeNewswire Inc

Dec 10, 2021

08:00AM EST Generated record net revenues of $19.6 million for the third quarter of 2021 GlobeNewswire Inc

Dec 9, 2021

08:30AM EST Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a GlobeNewswire Inc

Dec 8, 2021

08:30AM EST Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 GlobeNewswire Inc

Dec 7, 2021

04:05PM EST Journey Medical Corporation (Journey Medical) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that management will present at the Benzinga Global Small Cap Conference, which is being held virtually from December 8 9, 2021. GlobeNewswire Inc

08:28AM EST Fortress Biotech, Cyprium Therapeutics And Sentynl Therapeutics Announce Initiation Of Rolling Submission Of A New Drug Application For CUTX-101, Copper Histidinate, For Treatment Of Menkes Disease Benzinga

08:00AM EST Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics GlobeNewswire Inc

Nov 29, 2021

08:00AM EST Journey Medical Corporation Introduces Expanded Board of Directors GlobeNewswire Inc

Nov 17, 2021

09:30AM EST Avenue Therapeutics Announces Exercise and Closing of GlobeNewswire Inc

Nov 16, 2021

04:01PM EST Journey Medical Corporation Announces Closing of Initial Public GlobeNewswire Inc

Nov 15, 2021

04:54PM EST Fortress Biotech Q3 EPS $(0.19) Down From $(0.07) YoY, Sales $21.10M Up From $9.21M YoY Benzinga

04:54PM EST CORRECTION: Fortress Biotech Q3 Adj. EPS $(0.19) Benzinga

04:43PM EST Fortress Biotech Q3 EPS $0.54 Up From $(0.07) YoY, Sales $21.10M Up From $9.21M YoY Benzinga

04:01PM EST Net revenue for third quarter of 2021 increased 123% year-over-year to $21.1 million, a quarterly record GlobeNewswire Inc

Nov 12, 2021

09:20AM EST Avenue Therapeutics Announces Closing of Public Offering of Common GlobeNewswire Inc

08:05AM EST Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2021. GlobeNewswire Inc

07:25AM EST Fortress Bio Subsidiary Journey Medical Prices IPO Of 3.52M Shares Benzinga

07:00AM EST Journey Medical Corporation (NASDAQ: DERM) (Journey Medical), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, and a subsidiary of Fortress Biotech, Inc. (NASDAQ: FBIO) (Fortress), today announced the pricing of its initial public offering of common stock. GlobeNewswire Inc

Nov 10, 2021

08:18AM EST Mustang Bio Announces Exclusive Worldwide License Agreement With Leiden University Medical Centre For Clinical-Stage Lentiviral Gene Therapy With Curative Potential For RAG1 Severe Combined Immunodeficiency Benzinga

08:00AM EST Agreement expands Mustangs pipeline of lentiviral gene therapies for SCID GlobeNewswire Inc

Nov 8, 2021

10:13AM EST Fortress Biotech's Journey Medical Announces IPO Expected To Price Between $10-$12/Share Benzinga

10:13AM EST Journey Medical Corporation Announces Launch of its Initial Public GlobeNewswire Inc

Nov 1, 2021

08:30AM EDT Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell GlobeNewswire Inc

Oct 25, 2021

07:00AM EDT Avenue Therapeutics Receives Interim Response to its Formal GlobeNewswire Inc

Oct 18, 2021

08:30AM EDT Fortress Biotech to Participate in Dawson James GlobeNewswire Inc

Oct 14, 2021

08:07AM EDT The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts Benzinga

06:12AM EDT The following are some of the stocks making big moves in Thursday's pre-market trading (as of 06.00 A.M. EDT). RTTNews

Oct 13, 2021

07:30PM EDT CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition PR Newswire

Oct 8, 2021

01:19PM EDT Fortress-Backed Cyprium's Formulated Copper Histidinate Shows Efficacy In Rare Pediatric Disease Benzinga

08:24AM EDT Cyprium Plans To Begin Rolling Submission Of NDA For RTTNews

08:09AM EDT Fortress Biotech Announces Positive Clinical Data For CUTX-101 On Menkes Disease Treatment; Stock Up RTTNews

08:03AM EDT UPDATE: Fortress Biotech Says Overall Survival Significantly Improved In Patients Treated With CUTX-101; Says Rolling Submission Of New Drug Application To FDA Planned To Begin In Q4 2021 Benzinga

08:02AM EDT Fortress Biotech and Cyprium Therapeutics Announce Clinical Data For CUTX-101, Copper Histidinate, Presented At 2021 American Academy Of Pediatrics National Conference & Exhibition Benzinga

08:00AM EDT Cyprium Therapeutics, a partner company of Fortress Biotech, is developing CUTX-101 for the treatment of Menkes disease GlobeNewswire Inc

Oct 6, 2021

08:00AM EDT Triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech1 GlobeNewswire Inc

Oct 5, 2021

08:39AM EDT Fortress Biotech Partner Journey Medical Corp Appoints Ernest De Paolantonio As Chief Financial Officer Benzinga

08:34AM EDT Journey Medical Appoints Ernest De Paolantonio As CFO RTTNews

08:30AM EDT Journey Medical Corporation (Journey Medical), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (Fortress) focused on identifying, acquiring, developing and strategically commercializing innovative, differentiated dermatology products, today announces the appointment of Ernest De Paolantonio as Chief Financial Officer, effective September 30, 2021. GlobeNewswire Inc

Sep 30, 2021

12:01PM EDT From BZ's Small Cap Healthcare Conference: Fortress Biotech CEO Dr. Lindsay A. Rosenwald Says Co's Cosibelimab Top-Line Results Anticipated In Q4 2021 Benzinga

11:55AM EDT From BZ's Small Cap Healthcare Conference: Fortress Biotech CEO Dr. Lindsay A. Rosenwald Says Co's Model Is Different Because It Is Not Bound By Disease Type Or Modality Type; Co Focuses On Opportunism And Diversification Benzinga

11:52AM EDT From BZ's Small Cap Healthcare Conference: Fortress Biotech CEO Dr. Lindsay A. Rosenwald Says Co Creates Value In Four Ways: Equity Value, Monetizations, PRVs and Revenue Sales & Royalties Benzinga

11:47AM EDT From BZ's Small Cap Healthcare Conference: Fortress Biotech CEO Dr. Lindsay A. Rosenwald Begins Speaking Benzinga

08:30AM EDT Mustang Bio to Participate in Chardans Virtual GlobeNewswire Inc

Sep 29, 2021

08:13AM EDT The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug Benzinga

07:07AM EDT Fortress Biotech Announces Receipt Of Notice Of Option Exercise From AstraZeneca To Fully Acquire Caelum Biosciences, A Company Founded By Fortress Biotech; Option Triggers Upfront Payment Of $150M To Caelum, Of Which $64M Is Payable To Fortress Benzinga

07:00AM EDT Option exercise triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech1 GlobeNewswire Inc

Sep 28, 2021

04:15PM EDT Fortress Biotech Reports In 8-K Filing Co's Subsidiary Journey Medical Has Been Victim Of Business E-Mail Compromise Cybersecurity Incident That Led To $9.5M In Wire Transfers Benzinga

08:42AM EDT Fortress Biotech To Participate In Benzinga Healthcare Small Cap Conference Sept. 30 Benzinga

08:30AM EDT Mustang Bio Announces MB-101 GlobeNewswire Inc

08:30AM EDT Fortress Biotech to Participate in the Benzinga Healthcare Small GlobeNewswire Inc

Sep 22, 2021

08:30AM EDT Checkpoint Therapeutics to Participate in the 2021 Cantor Virtual GlobeNewswire Inc

Sep 9, 2021

08:30AM EDT Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in two upcoming investor conferences. Details are as follows: GlobeNewswire Inc

08:30AM EDT Mustang Bio to Participate in Three September 2021 Investor GlobeNewswire Inc

08:30AM EDT Fortress Biotech to Participate in Three September 2021 Investor GlobeNewswire Inc

Aug 16, 2021

04:08PM EDT Fortress Biotech Q2 EPS $(0.17) Down From $(0.05) YoY, Sales $17.84M Up From $9.46M YoY Benzinga

04:01PM EDT Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2021. GlobeNewswire Inc

04:01PM EDT Net revenue for second quarter of 2021 increased 89% year-over-year to $17.8 million, a quarterly record GlobeNewswire Inc

Aug 2, 2021

08:00AM EDT Mustang Bio Receives European Medicines Agency PRIME Designation GlobeNewswire Inc

Jun 30, 2021

11:29AM EDT Dr. Reddy's Lab, Fortress Biotech Ink DFD-29 Collaboration Pact For Chronic Skin Disorder Benzinga

08:03AM EDT Journey Medical Corporation Enters Into A Definitive Agreement With Dr. Reddy's Laboratories Ltd. To Develop And Commercialize DFD-29 For Treatment Of Rosacea; Financial Details Not Disclosed Benzinga

08:00AM EDT Journey Medical Corporation Enters into a Definitive Agreement GlobeNewswire Inc

Jun 17, 2021

08:00AM EDT Mustang Bio Awarded Massachusetts Life Sciences Center Tax Incentive GlobeNewswire Inc

Jun 16, 2021

08:30AM EDT Mustang Bio to Present at the Raymond James Human Health GlobeNewswire Inc

Jun 14, 2021

07:00AM EDT Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that it has received a second Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) seeking approval for IV tramadol. GlobeNewswire Inc

Jun 11, 2021

07:28AM EDT Mustang Bio's CAR T Cell Therapy Achieves 93% ORR, 67% CR In Mid-Stage Leukemia Trial Benzinga

06:30AM EDT Data presented at the European Hematology Association 2021 Virtual Congress show favorable safety profile and compelling clinical activity GlobeNewswire Inc

Jun 7, 2021

08:00AM EDT Mustang Bio to Host Key Opinion Leader Webinar on MB-106 GlobeNewswire Inc

Jun 3, 2021

08:02AM EDT Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics Benzinga

Jun 1, 2021

08:30AM EDT Fortress Biotech to Participate in Three June 2021 Virtual GlobeNewswire Inc

May 19, 2021

08:00AM EDT Fortress Biotech Announces Webinar Hosted by ROTH Capital Partners GlobeNewswire Inc

May 18, 2021

08:00AM EDT Mustang Bio and City of Hope Announce First Patient Dosed in Phase GlobeNewswire Inc

May 17, 2021

07:25AM EDT Fortress Biotech Q1 EPS $(0.09) Beats $(0.16) Estimate, Sales $11.59M Miss $13.41M Estimate Benzinga

07:00AM EDT Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021 GlobeNewswire Inc

May 14, 2021

04:30PM EDT Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2021. GlobeNewswire Inc

May 12, 2021

12:46PM EDT Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected For Presentation At European Hematology Association 2021 Virtual Congress Benzinga

12:45PM EDT Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for GlobeNewswire Inc

08:00AM EDT -- Top-line results expected in 4Q 2021 -- Targeting BLA submission in 1H 2022 -- Market-disruptive pricing planned in $25 billion and growing PD-(L)1 market GlobeNewswire Inc

May 10, 2021

07:35AM EDT Mustang Bio Announces FDA Acceptance Of IND Application For MB-106 CD20-Targeted CAR T Therapy Benzinga

07:30AM EDT The Phase 1/2 multicenter study to assess the safety, tolerability and efficacy of MB-106 in patients with relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia is expected to begin enrolling patients in the third quarter of this year GlobeNewswire Inc

07:05AM EDT Fortress Biotech Enters Licensing Agreement With Fuji Yakuhin For Dotinurad In US, UK, EU, Canada RTTNews

06:32AM EDT Fortress Biotech Enters a License Agreement with Fuji Yakuhin to Develop Dotinurad in the United State, UK, European Union and Canada Benzinga

06:30AM EDT Agreement signed with Fuji Yakuhin to develop Dotinurad, a potential best-in-class urate transporter (URAT1) inhibitor for gout and potentially other hyperuricemic indications including chronic kidney disease and heart failure GlobeNewswire Inc

Apr 21, 2021

08:00AM EDT Mustang Bio to Participate in Chardans 5th GlobeNewswire Inc

Apr 20, 2021

08:30AM EDT Roth Capital Maintains Buy on Fortress Biotech, Raises Price Target to $5 Benzinga

Apr 13, 2021

02:30PM EDT Mid-Afternoon Market Update: Dow Falls 75 Points; vTv Therapeutics Shares Spike Higher Benzinga

12:28PM EDT Mid-Day Market Update: Nasdaq Jumps 100 Points; Avenue Therapeutics Shares Slide Benzinga

08:16AM EDT The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug Benzinga

06:51AM EDT Avenue Therapeutics, Inc. (ATXI) said the FDA was still reviewing its New Drug Application for IV tramadol. The NDA was resubmitted following the receipt of official minutes from a Type A meeting with the FDA, which was conducted following a CRL issued by the FDA in October 2020. The resubmission had been assigned a PDUFA goal date of April 12, 2021. RTTNews

06:30AM EDT Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that the U.S. Food and Drug Administration (FDA) was still reviewing its New Drug Application (NDA) for IV tramadol and had not provided a decision regarding the NDA. GlobeNewswire Inc

Apr 10, 2021

09:19AM EDT The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight Benzinga

Apr 7, 2021

08:30AM EDT Fortress Biotech to Participate in the 20th Annual Needham Virtual GlobeNewswire Inc

Apr 6, 2021

09:07AM EDT Novel Cancer Therapy Phase 3 Trial Expects To Be Completed Shortly Benzinga

Apr 5, 2021

07:08AM EDT Fortress Biotech Partner Company Journey Medical Enters Into An Agreement With East West Bank In Which EWB Will Provide A $7.5M Working Capital Line Of Credit Benzinga

07:00AM EDT Journey Medical Corporation (Journey Medical), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (Fortress), today announced that it has entered into an agreement with East West Bank (EWB) in which EWB will provide a $7.5 million working capital line of credit. GlobeNewswire Inc

Apr 1, 2021

09:37AM EDT Fortress Biotech's Partner Firm Expands Footprint In Dermatology With Qbrexza Acquisition Benzinga

07:15AM EDT Journey Medical To Acquire QBREXZA In The U.S. From Dermira RTTNews

07:03AM EDT Fortress Biotech Partner Journey Medical To Acquire QBREXZA In The US From Dermira For; Financial Details Not Disclosed Benzinga

07:00AM EDT Journey Medical Corporation (Journey Medical), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (Fortress), today announced that it has entered into a definitive agreement to acquire QBREXZA (glycopyrronium) in the U.S. from Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company. GlobeNewswire Inc

Mar 31, 2021

04:33PM EDT Fortress Biotech FY20 Product Revenue $44.5M, Up From $34.9M YoY Benzinga

04:27PM EDT Fortress Biotech Reports FY20 EPS $(0.65) Up From $(0.73) YoY, Sales $45.6M Up From $36.6M YoY Benzinga

04:18PM EDT Fortress Biotech FY20 Sales $44.5M, Up From $34.9M YoY Benzinga

04:15PM EDT Revenue from marketed dermatology products increased 28% for full-year 2020 compared to 2019 GlobeNewswire Inc

Mar 24, 2021

04:30PM EDT Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the full year ended December 31, 2020. GlobeNewswire Inc

Mar 22, 2021

09:00AM EDT Fortress Biotech Reports Its Partner Company, Journey Medical, In Licenses, Launches Accutane For Treatment Of Severe Recalcitrant Nodular Acne Benzinga

09:00AM EDT Fortress Biotechs Partner Company, Journey GlobeNewswire Inc

Mar 9, 2021

04:30PM EST Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2020 and recent corporate highlights. GlobeNewswire Inc

Mar 4, 2021

08:00AM EST Fortress Biotech to Participate in Four March 2021 Virtual GlobeNewswire Inc

08:00AM EST Checkpoint Therapeutics to Participate in H.C. Wainwright Global GlobeNewswire Inc

08:00AM EST Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Mustangs management team will participate in three virtual investor conferences in March 2021. GlobeNewswire Inc

Mar 3, 2021

07:46AM EST The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study Benzinga

Mar 1, 2021

08:30AM EST Checkpoint Therapeutics Announces Formation of Scientific Advisory GlobeNewswire Inc

08:06AM EST Caelum Biosciences Announces Collaborations with the Amyloidosis Advocacy Community and Support of Amyloidosis Awareness Month Benzinga

08:00AM EST Caelum Biosciences Announces Collaborations with the Amyloidosis GlobeNewswire Inc

Feb 27, 2021

09:04PM EST The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings Benzinga

Feb 26, 2021

08:00AM EST Mustang Bio Joins Global Movement to Raise Awareness for Rare GlobeNewswire Inc

08:00AM EST Fortress Biotech Joins Global Movement to Raise Awareness for Rare GlobeNewswire Inc

Feb 24, 2021

09:20AM EST Fortress Biotech's Partner Offloads CUTX-101 To Sentynl Therapeutics Benzinga

08:00AM EST Sentynl acquires CUTX-101, Copper Histidinate, for $20 million in upfront and regulatory milestone payments through NDA approval, as well as potential sales milestones plus royalties GlobeNewswire Inc

Feb 23, 2021

09:08AM EST Fortress Biotech CEO Explains The Company's Three-Step Business Model Benzinga

Feb 22, 2021

08:10AM EST Aevitas Therapeutics Appoints Markus Peters, Ph.D., M.Sc., as CEO Benzinga

08:00AM EST Catherine Bowes Rickman, Ph.D., FARVO, a leading age-related macular degeneration researcher, appointed to Scientific Advisory Board GlobeNewswire Inc

Feb 2, 2021

07:42AM EST Mustang Bio Announces FDA Removes Clinical Hold For Pivotal Phase 2 MB-107 Clinical Trial; Plans To Enroll First Patient In MB-107 Pivotal Trial In Q2 Of 2021 Benzinga

07:30AM EST Mustang Bio Provides Updates on its Lentiviral Gene Therapies for GlobeNewswire Inc

Jan 25, 2021

11:30AM EST The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

Jan 23, 2021

03:15PM EST FBIO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Reminds Fortress Biotech, Inc. PR Newswire

Jan 22, 2021

11:00AM EST FBIO Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Fortress Biotech, Inc. Investors of Class Action and Lead Plaintiff Deadline: January 26, 2021 Business Wire

09:01AM EST Action Lawsuit Against Fortress Biotech, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm PR Newswire

Jan 21, 2021

05:00PM EST ROSEN, TRUSTED INVESTOR COUNSEL, Reminds Fortress Biotech, Inc. GlobeNewswire Inc

11:00AM EST The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

Jan 20, 2021

09:00PM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 2019 and October 9, 2020, inclusive (the Class Period). GlobeNewswire Inc

07:25PM EST Investors with losses are encouraged to contact the firm before January 26, 2021; click here to submit trade information GlobeNewswire Inc

11:00AM EST FBIO, NAK & SPLK Class Actions: Bronstein, Gewirtz & Grossman LLC GlobeNewswire Inc

11:00AM EST Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

Jan 19, 2021

09:00PM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Fortress Biotech, Inc. (NASDAQ: FBIO) from December 11, 2019 through October 9, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Fortress Biotech, Inc. investors under the federal securities laws. GlobeNewswire Inc

11:30AM EST Glancy Prongay & Murray LLP (GPM) reminds investors of the upcomingJanuary 26, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased or otherwise acquired Fortress Biotech, Inc. (Fortress or the Company) (NASDAQ: FBIO) securities between December 11, 2019 and October 9, 2020, inclusive (the Class Period). GlobeNewswire Inc

Jan 16, 2021

12:20PM EST ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Fortress Biotech, Inc. GlobeNewswire Inc

Jan 12, 2021

08:49PM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Fortress Biotech, Inc. (NASDAQ: FBIO) from December 11, 2019 through October 9, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Fortress Biotech, Inc. investors under the federal securities laws. GlobeNewswire Inc

Jan 11, 2021

12:30PM EST Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

Jan 9, 2021

04:03PM EST Investors of Important January 26 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - FBIO PR Newswire

Jan 8, 2021

07:15PM EST ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Reminds Fortress GlobeNewswire Inc

04:15PM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 2019 and October 9, 2020, inclusive (the Class Period). GlobeNewswire Inc

Jan 6, 2021

01:21PM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Fortress Biotech, Inc. (NASDAQ: FBIO) from December 11, 2019 through October 9, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Fortress Biotech, Inc. investors under the federal securities laws. GlobeNewswire Inc

12:00PM EST Glancy Prongay & Murray LLP (GPM) reminds investors of the upcomingJanuary 26, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased or otherwise acquired Fortress Biotech, Inc. (Fortress or the Company) (NASDAQ: FBIO) securities between December 11, 2019 and October 9, 2020, inclusive (the Class Period). GlobeNewswire Inc

08:30AM EST Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in three virtual investor conferences in January 2021. GlobeNewswire Inc

Jan 5, 2021

08:30AM EST Mustang Bio to Participate in Three January 2021 Virtual Investor GlobeNewswire Inc

08:30AM EST Fortress Biotech to Participate in Three January 2021 Virtual GlobeNewswire Inc

Jan 4, 2021

11:36AM EST Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

Jan 2, 2021

10:34AM EST ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Fortress Biotech, GlobeNewswire Inc

Dec 31, 2020

12:00PM EST FBIO Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC GlobeNewswire Inc

Dec 30, 2020

10:57AM EST Action Lawsuit Against Fortress Biotech, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm PR Newswire

Dec 29, 2020

11:00AM EST FBIO, NAK & SPLK Class Actions: Bronstein, Gewirtz & Grossman LLC GlobeNewswire Inc

Dec 28, 2020

12:30PM EST Glancy Prongay & Murray LLP (GPM) reminds investors of the upcomingJanuary 26, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased or otherwise acquired Fortress Biotech, Inc. (Fortress or the Company) (NASDAQ: FBIO) securities between December 11, 2019 and October 9, 2020 inclusive (the Class Period). GlobeNewswire Inc

11:18AM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Fortress Biotech, Inc. (NASDAQ: FBIO) from December 11, 2019 through October 9, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Fortress Biotech, Inc. investors under the federal securities laws. GlobeNewswire Inc

11:15AM EST The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

Dec 24, 2020

08:15AM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 2019 and October 9, 2020, inclusive (the Class Period). GlobeNewswire Inc

Dec 22, 2020

03:00PM EST LEADING ROSEN LAW FIRM Reminds Fortress Biotech, Inc. Investors of GlobeNewswire Inc

Dec 21, 2020

01:48PM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Fortress Biotech, Inc. (NASDAQ: FBIO) from December 11, 2019 through October 9, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Fortress Biotech, Inc. investors under the federal securities laws. GlobeNewswire Inc

12:00PM EST Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

08:04AM EST Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 to Treat Leptomeningeal Brain Tumors Benzinga

08:00AM EST Mustang Bio and City of Hope Announce Initiation of Phase 1 GlobeNewswire Inc

Dec 19, 2020

07:41PM EST SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Dec 18, 2020

12:01PM EST Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming PR Newswire

11:03AM EST Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of K12 Inc. (K12) (NYSE: LRN) and Fortress Biotech, Inc. (Fortress Biotech or the Company) (NASDAQ: FBIO) to determine whether K12 and Fortress Biotech engaged in securities fraud or other unlawful business practices. GlobeNewswire Inc

08:00AM EST Avenue Therapeutics Announces Publication of Tramadol Non-Medical GlobeNewswire Inc

08:00AM EST Avenue Therapeutics Announces Publication of Real-World Data on GlobeNewswire Inc

Dec 17, 2020

10:00PM EST of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - FBIO PR Newswire

07:00AM EST Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today provided a regulatory update following receipt of the official meeting minutes from a November 2020 Type A meeting with the U.S. Food and Drug Administration (FDA) relating to a path forward for IV tramadol. GlobeNewswire Inc

Dec 16, 2020

12:30PM EST Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class PR Newswire

Dec 15, 2020

05:45PM EST ROSEN, LEADING INVESTOR COUNSEL, Reminds Fortress Biotech, Inc. GlobeNewswire Inc

08:16AM EST Fortress Biotech Says FDA Granted Breakthrough Therapy Designation To Cyprium For CUTX-101 RTTNews

08:01AM EST Fortress Biotech Announces 'Breakthrough Therapy Designation' For CUTX-101 For Treatment Of Menkes Disease Benzinga

08:00AM EST Fortress Biotech Announces Breakthrough Therapy Designation for GlobeNewswire Inc

Dec 12, 2020

11:08PM EST SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

09:00AM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 2019 and October 9, 2020, inclusive (the Class Period). GlobeNewswire Inc

Dec 11, 2020

Dec 10, 2020

07:05PM EST ROSEN, A LEADING AND RESPECTED LAW FIRM, Reminds Fortress Biotech, GlobeNewswire Inc

Dec 9, 2020

11:33AM EST Biotech CEOs Talk Vision, Cash Burn, Catalysts At Benzinga Global Small Cap Conference Benzinga

11:00AM EST FBIO Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Fortress Biotech, Inc. Investors of Class Action and Lead Plaintiff Deadline: January 26, 2021 Business Wire

10:00AM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Fortress Biotech, Inc. (NASDAQ: FBIO) from December 11, 2019 through October 9, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Fortress Biotech, Inc. investors under the federal securities laws. GlobeNewswire Inc

09:08AM EST From BZ Small Cap Event: Fortress Biotech CEO Lindsay Rosenwald Notes The Company Attempts To Increase Shareholder Value By Revenue Sales and Royalties, Equity Values, PRVs, and Monetizations Benzinga

09:08AM EST From BZ Small Cap Event: Fortress Biotech CEO Lindsay Rosenwald Notes The Company Looks For Revenue Sales and Royalties, Equity Values, PRVs, and Monetizations Benzinga

09:07AM EST From BZ Small Cap Event: Fortress Biotech CEO Lindsay Rosenwald Notes The Company Attempts To Find Drug Candidates That Are In The Clinic That Appear To Be Effective Benzinga

09:07AM EST From BZ Small Cap Event: Fortress Biotech CEO Lindsay Rosenwald Notes The Company Looks For Relatively De-Risked Portfolio Of Assets And Low Acquisition Costs Benzinga

09:07AM EST From BZ Small Cap Event: Fortress Biotech CEO Lindsay Rosenwald Notes The Strategy For The Co. Is To Build A Pipeline Of Both Development Stage And Commercial Stage Assets And Leverage The Most Efficient Courses To Move Products Forward With Our Partners Benzinga

Dec 8, 2020

03:54PM EST From BZ Small Cap Event: Fortress Biotech CEO Lindsay Rosenwald Notes The Company Attempts To Increase Shareholder Value By Revenue Sales and Royalties, Equity Values, PRVs, and Monetizations Benzinga

03:50PM EST From BZ Small Cap Event: Fortress Biotech CEO Lindsay Rosenwald Notes The Company Looks For Revenue Sales and Royalties, Equity Values, PRVs, and Monetizations Benzinga

03:48PM EST From BZ Small Cap Event: Fortress Biotech CEO Lindsay Rosenwald Notes The Company Attempts To Find Drug Candidates That Are In The Clinic That Appear To Be Effective Benzinga

03:46PM EST From BZ Small Cap Event: Fortress Biotech CEO Lindsay Rosenwald Notes The Company Looks For Relatively De-Risked Portfolio Of Assets And Low Acquisition Costs Benzinga

03:45PM EST From BZ Small Cap Event: Fortress Biotech CEO Lindsay Rosenwald Notes The Strategy For The Co. Is To Build A Pipeline Of Both Development Stage And Commercial Stage Assets And Leverage The Most Efficient Courses To Move Products Forward With Our Partners Benzinga

Dec 7, 2020

09:11PM EST SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

05:22PM EST Schedule Of NYSE-, Nasdaq-Listed Publicly-Traded Companies Presenting At Benzinga's Small Cap Conference Dec. 8-9 Benzinga

07:30AM EST Data presented at the 62nd American Society of Hematology (ASH) Annual Meetingshow extremely favorable safety profile and clinical activity GlobeNewswire Inc

Dec 6, 2020

08:41AM EST Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace Benzinga

Dec 5, 2020

07:27AM EST Lawsuit Against Fortress Biotech, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - FBIO PR Newswire

Dec 4, 2020

Dec 3, 2020

12:16PM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 2019 and October 9, 2020, inclusive (the Class Period). GlobeNewswire Inc

Dec 1, 2020

05:51PM EST Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 2019 to October 9, 2020, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Fortress investors under the federal securities laws. GlobeNewswire Inc

10:01AM EST Biotech, Inc. Investors of Class Action and Lead Plaintiff Deadline: January 26, 2021 PR Newswire

08:00AM EST Mustang Bio to Host Key Opinion Leader Call on MB-106 for the GlobeNewswire Inc

Nov 30, 2020

02:39PM EST Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Fortress Biotech, Inc. (Fortress Biotech or the Company) (NASDAQ: FBIO) to determine whether the Company engaged in securities fraud or other unlawful business practices. GlobeNewswire Inc

Nov 29, 2020

08:59AM EST The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions Benzinga

Nov 27, 2020

05:58PM EST Pomerantz Law Firm Announces the Filing of a Class Action against Fortress PR Newswire

Nov 24, 2020

08:00AM EST Mustang Bio Announces Positive Opinion from the European Medicines GlobeNewswire Inc

Nov 23, 2020

08:00AM EST Mustang Bio and Minaris Regenerative Medicine Sign Technology GlobeNewswire Inc

Nov 18, 2020

08:00AM EST Fortress Biotech Ranked in Deloittes Technology GlobeNewswire Inc

Nov 9, 2020

04:52PM EST Fortress Biotech Q3 EPS $(0.07) Up From $(0.22) YoY, Sales $9.40M Down From $9.77M YoY Benzinga

08:29AM EST Checkpoint Therapeutics Announces Presentation Of Updated Cosibelimab Lung Cancer Results At The Society For Immunotherapy Of Cancer (SITC) 35th Anniversary Annual Meeting Benzinga

08:00AM EST -- 44.0% objective response rate and 10.3-monthmedian progression-free survival observed in non-small cell lung cancer (NSCLC) cohort -- Phase 3 registration-enablingtrial planned in first-line metastatic NSCLC GlobeNewswire Inc

Nov 6, 2020

04:20PM EST Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2020. GlobeNewswire Inc

Nov 4, 2020

04:25PM EST Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced financial results for the third quarter ended September 30, 2020, and recent corporate highlights. GlobeNewswire Inc

12:15PM EST Fortress Biotech Announces Oral and Poster Data Presentations at GlobeNewswire Inc

09:25AM EST Mustang Bio Announces MB-106 Data Selected for Presentation at the GlobeNewswire Inc

Nov 2, 2020

07:01AM EST Samsung Biologics and Checkpoint Therapeutics Expand Manufacturing Partnership PR Newswire

Oct 26, 2020

08:11AM EDT Mustang Bio Announces Initial Phase 1 Data On MB-105 For Patients With PSCA-Positive Castration Resistant Prostate Cancer Benzinga

08:01AM EDT Mustang Bio Announces Initial Phase 1 Data on MB-105 for Patients GlobeNewswire Inc

Oct 19, 2020

08:33AM EDT Fortress Biotech's Partner Company Journey Medical Corporation To Be Featured In Webinar Hosted By ROTH Capital Partners Benzinga

08:30AM EDT Fortress Biotechs Partner Company, Journey GlobeNewswire Inc

Oct 14, 2020

09:08PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of PR Newswire

Oct 13, 2020

09:56AM EDT Roth Capital Maintains Buy on Fortress Biotech, Lowers Price Target to $4.75 Benzinga

Oct 12, 2020

12:07PM EDT HC Wainwright & Co. Maintains Buy on Fortress Biotech, Lowers Price Target to $10 Benzinga

10:48AM EDT Why Fortress Biotech's Stock Is Trading Lower Today Benzinga

06:33AM EDT Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol Benzinga

06:30AM EDT Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Companys New Drug Application (NDA) for IV tramadol. GlobeNewswire Inc

Oct 8, 2020

08:01AM EDT Mustang Bio Announces MB-105 Data Selected For Presentation At The Virtual 27th Annual Prostate Cancer Foundation Scientific Retreat Benzinga

08:00AM EDT Mustang Bio Announces MB-105 Data Selected for Presentation at the GlobeNewswire Inc

Oct 6, 2020

08:11AM EDT Mustang Bio Licenses LentiBOOST Technology From SIRION Biotech Benzinga

08:01AM EDT Mustang Bio Licenses GlobeNewswire Inc

Oct 2, 2020

10:39AM EDT Benzinga's Top Upgrades, Downgrades For October 2, 2020 Benzinga

07:51AM EDT Benchmark Initiates Coverage On Fortress Biotech with Buy Rating, Announces Price Target of $9 Benzinga

Oct 1, 2020

08:30AM EDT Mustang Bio to Participate in Chardans Virtual GlobeNewswire Inc

08:01AM EDT Mustang Bio Announces First Patient Dosed in Multicenter Phase 1/2 GlobeNewswire Inc

Sep 22, 2020

08:09AM EDT Mustang Bio Announces Orphan Drug Designation For MB-207 For Treatment Of X-Linked Severe Combined Immunodeficiency In Previously Transplanted Patients Benzinga

08:01AM EDT Mustang Bio Announces Orphan Drug Designation for MB-207 for the GlobeNewswire Inc

Sep 17, 2020

05:27PM EDT Checkpoint Therapeutics Announces $20.0 Million Bought Deal Offering GlobeNewswire Inc

document.getElementById("M8QP24").onerror = function(){this.style.display='none';}; .dark-mode .rssjPR{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .rssjPR{ color: #333333; background-color: white; border: 2px solid #333333; }FBIOFortress Biotech, Inc.stock NASDAQ

FBIO
Fortress Biotech, Inc.
stock NASDAQ